British drugmaker AstraZeneca Plc said its cancer drug Imfinzi has been granted a speedy review by the US Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.
The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.
A final decision is expected in the first quarter of 2020.